Conference Proceedings
Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
S Loi, P Schmid, J Cortes, YH ark, E Munoz-Couselo, S-B Kim, J Sohn, S-A Im, E Holgado, T Foukakis, S Kuemmel, R Dent, A Wang, G Aktan, V Karantza, R Salgado
CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2019
Abstract
Abstract Background:Increasing quantities of stromal TILs (sTILs) are associated with higher pathologic complete response (pCR) rates with conventional chemo in early-stage TNBC. We evaluated the association between sTILs and PD-L1 expression with response to pembro+chemo as NAT for TNBC in the KEYNOTE-173 trial (NCT02622074). Methods: sTILs were quantified using light microscopy of H&E-stained slides from pretreatment and on-treatment (during first 3 weeks of pembro monotherapy) tumor biopsies by a pathologist blind to response data. Pretreatment PD-L1 expression was assessed using the PD-L1 IHC 22C3 pharmDx assay and reported as combined positive score (CPS). ..
View full abstract